文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

瑞马唑仑对超重或肥胖患者辅助生殖镇静宫腔镜检查中重度低氧血症发生率的影响:一项随机对照临床试验

The effects of remimazolam on the incidence of severe hypoxemia during sedated hysteroscopy for assisted reproduction in overweight or obese patients: a randomized controlled clinical trial.
PubMed 文献 · Trials · 2025-08-26

本研究为前瞻性、单中心、随机、单盲、对照临床试验,计划纳入600例拟行镇静宫腔镜检查的超重或肥胖患者,随机分为丙泊酚对照组与瑞马唑仑试验组,主要目的是确定瑞马唑仑能否降低该类患者宫腔镜检查中重度低氧血症的发生率,并为其安全性与有效性提供证据。

要点

  • 超重或肥胖患者镇静宫腔镜检查中,瑞马唑仑与丙泊酚的安全性和有效性将被比较。
  • 研究主要结局为重度低氧血症发生率,计划纳入600例患者。
  • 试验注册于ClinicalTrials.gov,注册号NCT06187896,注册日期2024年1月3日。

核心结论

  • 本研究旨在确定瑞马唑仑能否降低超重或肥胖患者宫腔镜检查中重度低氧血症的发生率。
  • 研究结果预期为瑞马唑仑在超重或肥胖患者中的安全性与有效性提供证据,以提升镇静宫腔镜检查中的患者舒适度与安全性。

研究设计与样本

  • 前瞻性、单中心、随机、单盲、对照临床试验。
  • 计划纳入600例拟行镇静宫腔镜检查的患者,随机分配至对照组或试验组,分别使用丙泊酚或瑞马唑仑进行镇静。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypoxemia is the most common adverse reaction during sedated hysteroscopy. Obesity is a risk factor for hypoxemia. For hysteroscopy, propofol is the most commonly used sedative. However, it can cause dose-dependent respiratory depression. This drawback has driven the search for sedatives with less respiratory depressant effects. Remimazolam is a new benzodiazepine drug with several advantages, including minimal impact on the respiratory and circulatory systems. This study aims to compare remimazolam and propofol in terms of safety and efficacy in patients with overweight or obesity who are undergoing sedated hysteroscopy. METHODS: This prospective, single-center, randomized, single-blind, controlled clinical trial will be conducted to examine the effect of remimazolam on the incidence of severe hypoxemia in patients with overweight or obesity. Patients (n = 600) scheduled to undergo sedated hysteroscopy will be randomly assigned to either the control or experimental group and will be sedated using propofol or remimazolam, respectively. DISCUSSION: The main objective of this study is to determine whether remimazolam can reduce the incidence of severe hypoxemia in patients with overweight or obesity during hysteroscopy. The results of this study are expected to provide evidence on the safety and efficacy of remimazolam in patients with overweight or obesity, which will enhance patient comfort and safety during sedated hysteroscopy. TRIAL REGISTRATION: ClinicalTrials.gov NCT06187896. Registered on January 3, 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. He Y, Zhou J, Ding X, et al. The effects of remimazolam on the incidence of severe hypoxemia during sedated hysteroscopy for assisted reproduction in overweight or obese patients: a randomized controlled clinical trial. Trials. 2025. PMID: 40859372. doi:10.1186/s13063-025-09054-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。